Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01992185 · ClinicalTrials.gov registry record · NA
Photocil (Topical) for the Treatment of Vitiligo
A NA study of Vitiligo, sponsored by Applied Biology.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01992185 is a NA study of Vitiligo that has completed, run by Applied Biology. The registered enrollment target is 15 participants, below the 1,123-participant average among 15 other Vitiligo trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01992185, a NA study of Vitiligo, has completed, sponsored by Applied Biology.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight. Photocil is intended to help protect users from non-therapeutic Ultraviolet B (UVB) radiation while selectively passing wavelengths of light in the NB-UVB range with peak transmission of 308nm. The aim of the study is to assess the safety and efficacy of Photocil in the treatment of vitiligo.
Conditions Studied
Interventions
- DRUG Photocil for Vitiligo
- OTHER Placebo - Sunscreen (SPF 2)
Study Locations (1)
Arizona
- Physicians Institute - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01992185
The ClinicalTrials.gov registry entry for NCT01992185 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,123-participant average among 15 other Vitiligo trials with a reported enrollment target (99% lower). The listed sponsor is Applied Biology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Photocil for Vitiligo is the first listed.
NCT01992185 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT01992185 about?
NCT01992185 is a clinical study titled "Photocil (Topical) for the Treatment of Vitiligo". Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight. Photocil is intended to help protect users from non-therapeutic Ultraviolet B (UVB) radiation while selectively passing wavelengths of light in the NB-UVB range with pe...
What is the current status of trial NCT01992185?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2013-08. Estimated completion is 2014-12.
What conditions does trial NCT01992185 study?
This clinical trial studies the following conditions: Vitiligo.
What interventions are being tested in trial NCT01992185?
The interventions under investigation include: Photocil for Vitiligo (DRUG), Placebo - Sunscreen (SPF 2) (OTHER).
Who is sponsoring clinical trial NCT01992185?
This trial is sponsored by Applied Biology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01992185 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy
COMPLETED · NA
-
Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells
COMPLETED · NA
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
-
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
-
The Gut and Skin Microbiome in Vitiligo Disease Progression
RECRUITING
-
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.